Osilodrostat for cushing syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Aug 2025: Trial registered, NCT07104812
  2. 14 Jan 2026: Trial started, NCT07104812

The trials

NCT07104812: Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

State
Under way
Phase
Phase 2
People
15 planned
Started
14 Jan 2026
Primary completion
Jan 2027
Arms
Mild autonomous cortisol secretion (MACS)
Results
None posted
  1. 5 Aug 2025: Trial registered
  2. 14 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Osilodrostat 1 MG.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.